Brief: Guardant Health Q2 Adjusted EPS USD -0.42 Vs. IBES Estimate USD -0.41
30/07/2026 21:06
BRIEF-Guardant Health Q2 Adjusted EPS USD -0.42 Vs. IBES Estimate USD -0.41 Jul 30 (Reuters) - Guardant Health Q2 revenue USD 335 million vs. IBES estimate USD 314.2 million.
- Q2 EPS USD -0.9
- Q2 adjusted net income USD -56.2 million vs. IBES estimate USD -54.3 million
- Q2 adjusted EBITDA USD -55.9 million vs. IBES estimate USD -50.3 million
- outlook FY revenue USD 1,340-1,360 million vs. IBES estimate USD 1,314 million
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment